Past, Current, and Future of Immunotherapies for Prostate Cancer

Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of cancer related death in men in Western countries. The standard therapy for metastatic PCa is androgen suppression therapy (AST). Men undergoing AST eventually develop metastatic castration-resistant prostate canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Boettcher, Adeline N., Usman, Ahmed, Morgans, Alicia, VanderWeele, David J., Sosman, Jeffrey, Wu, Jennifer D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749031/
https://www.ncbi.nlm.nih.gov/pubmed/31572678
http://dx.doi.org/10.3389/fonc.2019.00884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749031/
https://www.ncbi.nlm.nih.gov/pubmed/31572678
http://dx.doi.org/10.3389/fonc.2019.00884

Ejemplares similares